Prelude Capital Management’s SAB Biotherapeutics SABS Stock Holding History

Prelude Capital Management’s Portfolio SABS Stock Details SABS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$131K	Buy	+34,124	New	+$136K	0.01%	999

Other funds holding SABS

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Prelude Capital Management's SABS Position: Q1 2026 in Review

Prelude Capital Management opened a new position in SAB Biotherapeutics (SABS) in Q1 2026: 34,124 shares worth $131K. The stake represents 0.01% of the portfolio and ranks #999 among its holdings.

76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

Prelude Capital Management held 34,124 shares of SAB Biotherapeutics worth $131K as of Q1 2026.
SAB Biotherapeutics was a new Prelude Capital Management position in Q1 2026.
SAB Biotherapeutics made up 0.01% of Prelude Capital Management's portfolio in Q1 2026, its #999 holding.
76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.